Head-to-head comparison
| Property | Retatrutide | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~6 days | ~7 days |
| Mol. Weight | 4,894.58 Da | 4,113.58 Da |
| Side Effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Receptor targets: Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously; semaglutide activates GLP-1 receptors only.
- Weight loss efficacy: Phase II showed retatrutide (12 mg) achieved approximately 24% weight loss at 48 weeks; semaglutide (2.4 mg) achieved 15–17% at 68 weeks in STEP trials.
- Energy expenditure: Retatrutide's glucagon component increases resting energy expenditure; semaglutide's weight loss is driven primarily by appetite suppression and reduced caloric intake.
- Approval status: Semaglutide is FDA-approved with multiple indications and years of real-world data; retatrutide is in Phase III trials.
- Manufacturer: Retatrutide is developed by Eli Lilly; semaglutide by Novo Nordisk.
- Liver fat: Retatrutide Phase II showed substantial liver fat reduction, potentially relevant for MASH; semaglutide also reduces liver fat but less aggressively.
- Safety profile: Semaglutide has extensive Phase III and post-market safety data; retatrutide has Phase II safety data with Phase III ongoing.
The verdict
Retatrutide's Phase II data is remarkable — approximately 24% weight loss at 48 weeks would be the highest reported for any anti-obesity medication. The triple-agonist mechanism addresses obesity from multiple angles. However, semaglutide is FDA-approved, commercially available, and has years of safety data. Retatrutide is a promising pipeline candidate that must still prove itself in Phase III. For current treatment, semaglutide is the proven standard; retatrutide is the most exciting pipeline contender.
Frequently asked questions
If Phase III confirms Phase II results, retatrutide could become the preferred weight loss medication due to superior efficacy. However, semaglutide will likely remain a standard treatment option, similar to how semaglutide coexists with liraglutide. Market competition will depend on pricing, access, and safety profiles.
Phase II data showed approximately 24% weight loss with retatrutide at 48 weeks versus 15–17% with semaglutide at 68 weeks. This approximately 7 percentage point advantage is clinically meaningful if confirmed in Phase III trials.
Phase II data showed an acceptable safety profile with GI side effects similar to other incretin therapies. Phase III trials are underway to establish comprehensive safety data. Semaglutide has substantially more safety evidence from large Phase III trials and years of post-market surveillance.
No, they are competitors. Retatrutide is developed by Eli Lilly (which also makes tirzepatide), while semaglutide is developed by Novo Nordisk. This represents a major pipeline rivalry between the two leading obesity pharmaceutical companies.
Beyond GLP-1 (appetite suppression), retatrutide adds GIP (enhanced insulin sensitivity, fat metabolism) and glucagon (increased energy expenditure, hepatic fat oxidation). This three-pronged approach may explain the superior weight loss: reducing intake, improving metabolism, and increasing expenditure simultaneously.